Could a simple blood test replace invasive tissue biopsies for cancer genetics?

NCT ID NCT06606366

Recruiting now Diagnosis Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid the discomfort and risk of a traditional biopsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liquid biopsy (blood test for circulating tumor DNA)
What this could lead to: If successful, this could show that a simple blood test can reliably detect tumor genetics, potentially reducing the need for invasive tissue biopsies in advanced cancer patients.
What could go wrong: This is an observational comparison, not a treatment trial. The liquid biopsy may not be as accurate as the solid biopsy, and results may not apply to all cancer types or stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASM MALIGNANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASM MALIGNANT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Antoine Lacassagne
RECRUITING

Nice, 06189, France

Contact

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.